HC Wainwright Has Lowered Expectations for Avalo Therapeutics (NASDAQ:AVTX) Stock Price

Avalo Therapeutics (NASDAQ:AVTX) had its target price decreased by stock analysts at HC Wainwright from $35.00 to $30.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 60.43% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on the stock. Citizens Jmp decreased their price objective on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a report on Thursday, May 14th. Piper Sandler restated an “overweight” rating and set a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Bank of America assumed coverage on Avalo Therapeutics in a research report on Friday, June 12th. They issued a “buy” rating and a $35.00 price target for the company. Leerink Partners initiated coverage on Avalo Therapeutics in a research note on Monday, July 6th. They set an “outperform” rating and a $38.00 price target for the company. Finally, Wedbush lowered their price objective on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Avalo Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $45.30.

Avalo Therapeutics Stock Down 0.7%

NASDAQ AVTX opened at $18.70 on Friday. The stock has a market capitalization of $989.23 million, a PE ratio of -3.42 and a beta of 0.80. Avalo Therapeutics has a 12-month low of $8.01 and a 12-month high of $24.27. The company has a 50 day moving average price of $17.22 and a two-hundred day moving average price of $16.27.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, equities analysts anticipate that Avalo Therapeutics will post -2.58 EPS for the current year.

Insider Activity

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the sale, the insider owned 51,776 shares in the company, valued at $931,968. The trade was a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.46% of the company’s stock.

Institutional Trading of Avalo Therapeutics

Large investors have recently bought and sold shares of the stock. Boothbay Fund Management LLC bought a new position in shares of Avalo Therapeutics during the second quarter valued at $56,000. Dimensional Fund Advisors LP acquired a new stake in shares of Avalo Therapeutics during the 3rd quarter worth about $143,000. AlphaCentric Advisors LLC bought a new position in Avalo Therapeutics during the 1st quarter valued at about $174,000. Jump Financial LLC acquired a new position in Avalo Therapeutics in the fourth quarter valued at about $238,000. Finally, Persistent Asset Partners Ltd bought a new stake in Avalo Therapeutics during the fourth quarter worth about $274,000. 87.06% of the stock is currently owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.